Research programme: S6 kinase 1 inhibitors - Sentinel Oncology

Drug Profile

Research programme: S6 kinase 1 inhibitors - Sentinel Oncology

Alternative Names: FS 115; p70S6 inhibitors - Sentinel; p70S6K1 inhibitor - Sentinel; S6K1 inhibitors - Sentinel

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Sentinel Oncology
  • Class Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 02 Dec 2016 Pharmacokinetics and pharmacodynamics data from a preclinical trial in Breast cancer presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2016)
  • 09 Aug 2016 Preclinical trials in Breast cancer in United Kingdom (PO)
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top